Welcome to our dedicated page for 60 Degrees Pharm SEC filings (Ticker: SXTPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for 60 Degrees Pharmaceuticals, Inc. (warrants trading under SXTPW) provides access to the company’s official disclosures as a Nasdaq-listed emerging growth company in the medicinal and botanical manufacturing industry. These filings cover the common stock (SXTP), associated warrants (SXTPW), and a range of corporate, financing, and clinical development activities.
Through documents such as Form 8-K, investors can review material events, including at-the-market sales agreements for common stock, termination of prior ATM arrangements, and investor presentation updates. Filings also identify the company’s status as a Delaware corporation, its listing of common stock and warrants on The Nasdaq Stock Market LLC, and its classification as a smaller reporting company and emerging growth company.
Registration statements like the Form S-1 filed in July 2025 describe proposed offerings of common stock, pre-funded warrants, and series A-1 and A-2 warrants, along with placement agent warrants. These documents outline the terms of the securities, potential gross proceeds, use of proceeds for general corporate purposes and working capital, and risk factors associated with investing in the company’s securities.
Annual and quarterly reports (when available on EDGAR) provide more comprehensive information on 60 Degrees Pharmaceuticals’ business, including its focus on vector-borne diseases, FDA-approved malaria prophylaxis product ARAKODA (tafenoquine), and company-sponsored babesiosis clinical trials. Proxy materials and other filings may address corporate governance matters and equity incentive plans that affect both common shareholders and warrant holders.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of new registration statements, 8-K disclosures, or updates related to ARAKODA and babesiosis programs. Users can monitor real-time filing updates from EDGAR, track how warrant-related offerings and reverse stock splits are structured, and reference Forms 10-K and 10-Q for a broader view of financial condition and risk disclosures.
60 Degrees Pharmaceuticals is a specialty pharmaceutical company marketing the FDA-approved malaria prevention product Arakoda and developing additional tafenoquine-based and other programs. For the three months ended June 30, 2025 the company reported net revenue of $257,820 (including $100,932 product revenue and $206,939 research revenue) and a gross profit of $50,881. Cash and cash equivalents were $1,966,930 at June 30, 2025, up from $1,659,353 at December 31, 2024, aided by net financing proceeds of approximately $1.7 million from January and February 2025 registered offerings.
Despite the revenue increase, the company reported a six-month net loss of $3,612,231, used $3,047,494 in operating activities during the six months, and had an accumulated deficit of $44,138,232. Derivative liabilities tied to a contingent milestone (Knight) were $776,172. Management states there is substantial doubt about the company’s ability to continue as a going concern without raising additional capital. The company also faces customer concentration (significant customers comprised ~99% of product revenue for the quarter) and sole-vendor API supply risk.